Altria’s stock surges 6% in 2026 as FDA approval fuels investor optimism
Altria Group has witnessed growing investor confidence in the early stages of 2026. The tobacco giant's stock has climbed 6% since the start of the year, outperforming the broader stock market. Meanwhile, major financial firms have raised their price targets, and a key regulatory approval has added momentum to the company's prospects.
On January 19, Sequoia Financial Advisors LLC boosted its stake in Altria by 33.8%. The firm added 29,001 shares, bringing its total holdings to 114,851—worth roughly $7.59 million. This move was documented in a 13F filing with the SEC, covering the quarter ending December 31, 2025.
The company also received a regulatory win. The U.S. Food and Drug Administration approved the sale of Altria's on! Plus nicotine pouches in mint, tobacco, and wintergreen flavours. This decision expands the product's market reach. Analysts have taken notice of Altria's recent performance. UBS upgraded the stock to buy, predicting a potential rise to $63 per share. Goldman Sachs went further, lifting its price target to $72 while keeping a buy rating. The stock's high dividend yield of about 6.9% has further attracted investors.
Altria's share price has risen steadily since the year began. The FDA's approval of its nicotine pouches and upgraded analyst ratings suggest continued interest in the company. With a strong dividend yield and growing institutional backing, its market position appears reinforced.
